Received Aug 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y019463 | — |
Nurse called and reported PROQUAD was administered to a patient after being involved in a temperature excursion. Caller stated PROQUAD and VARIVAX were also administered to multiple other patients. See AE cases 02856250, 02856303, 02856304, 02856306,; Caller stated no patient symptoms have been reported; This spontaneous report was received from a licensed vocational nurse (L.V.N) and refers to a patient of unknown age and gender. The patient's medical history, historical drugs, known drug allergies, concurrent conditions, and concomitant therapies were not reported. On 11-Aug-2025, the patient started was vaccinated with the first dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), solution for injection (lot #Y019463, expiration date: 24-May-2026), reconstituted with sterile diluent (MERCK STERILE DILUENT), solution for injection (lot# and expiration date was not reported), 1 dose, as prophylaxis (route of administration and anatomical location were not reported); that was involved in a temperature excursion of -8C, during 15 minutes (a previous excursion had not occurred). The reporter stated no patient symptoms have been reported. This was one of 7 reports received by the same reporter.
Sterile diluent